Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

ARA-290 vs Wolverine

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

ARA-290 has stronger documented evidence (Phase 2) than Wolverine (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Wolverine may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

ARA-290

Phase 2

Wolverine

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

ARA-290 Wolverine
Class EPO-derived peptide; innate repair receptor (IRR) agonist Combination peptide stack
Drug class Tissue Repair Tissue Repair
Mechanism Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect Combined cytoprotective + actin regulation (see individual entries)
Route SC injection SC / IM
Half-life ~2 hrs See individual peptides
Dosage (research) 2-4 mg SC daily for 28 days (trial protocol) BPC 250-500 mcg + TB 2 mg SC daily or split weekly
Evidence tier Phase 2 Anecdotal
Research depth 68 indexed (PubMed 51 · CT 4 · EPMC 13) 1 indexed (PubMed 0 · CT 0 · EPMC 1)
Availability Investigational Compounding Restricted
Reported risks Injection site reactions; Phase 2/3 data limited Combined risk profile of both; no combination safety trials

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick ARA-290 or Wolverine?

ARA-290 has stronger documented evidence (Phase 2) than Wolverine (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Wolverine may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between ARA-290 and Wolverine?

ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist; Wolverine is classed as Combination peptide stack. Reported mechanism: ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect; Wolverine, Combined cytoprotective + actin regulation (see individual entries). Reported half-life: ARA-290, ~2 hrs; Wolverine, See individual peptides. Routes in published studies: ARA-290, SC injection; Wolverine, SC / IM.

Which has stronger evidence, ARA-290 or Wolverine?

ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies. Wolverine is graded Anecdotal, with 2 cited sources on its reference page and 1 indexed studies.

Which is more accessible, ARA-290 or Wolverine?

Neither ARA-290 nor Wolverine is an FDA-approved drug. Catalog status: ARA-290, Investigational; Wolverine, Compounding Restricted.

Are ARA-290 and Wolverine ever combined?

ARA-290 and Wolverine appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…